Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Bibliographic Details
Main Authors: D Papaioannou, R Rafia, J Rathbone, M Stevenson, H Buckley Woods, J Stevens
Format: Article
Language:English
Published: NIHR Journals Library 2012-10-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta16370
id doaj-ce0cbf05c2524f079e14cf50cb1d4f01
record_format Article
spelling doaj-ce0cbf05c2524f079e14cf50cb1d4f012020-11-24T22:03:18ZengNIHR Journals LibraryHealth Technology Assessment1366-52782012-10-01163710.3310/hta16370Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.D Papaioannou0R RafiaJ RathboneM StevensonH Buckley WoodsJ StevensSchool of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UKhttps://doi.org/10.3310/hta16370
collection DOAJ
language English
format Article
sources DOAJ
author D Papaioannou
R Rafia
J Rathbone
M Stevenson
H Buckley Woods
J Stevens
spellingShingle D Papaioannou
R Rafia
J Rathbone
M Stevenson
H Buckley Woods
J Stevens
Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Health Technology Assessment
author_facet D Papaioannou
R Rafia
J Rathbone
M Stevenson
H Buckley Woods
J Stevens
author_sort D Papaioannou
title Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
title_short Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
title_full Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
title_fullStr Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
title_full_unstemmed Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
title_sort rituximab for the first-line treatment of stage iii–iv follicular lymphoma (review of technology appraisal no. 110): a systematic review and economic evaluation.
publisher NIHR Journals Library
series Health Technology Assessment
issn 1366-5278
publishDate 2012-10-01
url https://doi.org/10.3310/hta16370
work_keys_str_mv AT dpapaioannou rituximabforthefirstlinetreatmentofstageiiiivfollicularlymphomareviewoftechnologyappraisalno110asystematicreviewandeconomicevaluation
AT rrafia rituximabforthefirstlinetreatmentofstageiiiivfollicularlymphomareviewoftechnologyappraisalno110asystematicreviewandeconomicevaluation
AT jrathbone rituximabforthefirstlinetreatmentofstageiiiivfollicularlymphomareviewoftechnologyappraisalno110asystematicreviewandeconomicevaluation
AT mstevenson rituximabforthefirstlinetreatmentofstageiiiivfollicularlymphomareviewoftechnologyappraisalno110asystematicreviewandeconomicevaluation
AT hbuckleywoods rituximabforthefirstlinetreatmentofstageiiiivfollicularlymphomareviewoftechnologyappraisalno110asystematicreviewandeconomicevaluation
AT jstevens rituximabforthefirstlinetreatmentofstageiiiivfollicularlymphomareviewoftechnologyappraisalno110asystematicreviewandeconomicevaluation
_version_ 1725832255382749184

Similar Items